ATE428803T1 - Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände - Google Patents

Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände

Info

Publication number
ATE428803T1
ATE428803T1 AT01270623T AT01270623T ATE428803T1 AT E428803 T1 ATE428803 T1 AT E428803T1 AT 01270623 T AT01270623 T AT 01270623T AT 01270623 T AT01270623 T AT 01270623T AT E428803 T1 ATE428803 T1 AT E428803T1
Authority
AT
Austria
Prior art keywords
expression
purinergem
preneoplastic
receptor
identify
Prior art date
Application number
AT01270623T
Other languages
English (en)
Inventor
Julian Barden
Michael Slater
Original Assignee
Biosceptre Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosceptre Pty Ltd filed Critical Biosceptre Pty Ltd
Application granted granted Critical
Publication of ATE428803T1 publication Critical patent/ATE428803T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01270623T 2000-12-11 2001-12-11 Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände ATE428803T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR2015A AUPR201500A0 (en) 2000-12-11 2000-12-11 Methods for identifying pre-neoplastic and neoplastic states in mammals
PCT/AU2001/001614 WO2002048395A1 (en) 2000-12-11 2001-12-11 P2y purinergic receptor expression for identifying preneoplastic and neoplastic states

Publications (1)

Publication Number Publication Date
ATE428803T1 true ATE428803T1 (de) 2009-05-15

Family

ID=3826050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01270623T ATE428803T1 (de) 2000-12-11 2001-12-11 Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände

Country Status (10)

Country Link
US (2) US20040067542A1 (de)
EP (1) EP1352085B1 (de)
JP (2) JP4334223B2 (de)
CN (1) CN100448486C (de)
AT (1) ATE428803T1 (de)
AU (1) AUPR201500A0 (de)
CA (1) CA2431362A1 (de)
DE (1) DE60138415D1 (de)
WO (1) WO2002048395A1 (de)
ZA (1) ZA200304853B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
FR2842424A1 (fr) * 2002-07-22 2004-01-23 Univ Paris 7 Denis Diderot Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20090215711A1 (en) * 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20090214420A1 (en) * 2005-04-01 2009-08-27 Medvet Science Pty. Ltd. Method of Diagnosis and Treatment and Agents Useful for Same
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (de) 2009-08-20 2015-09-30 Biosceptre International Limited Antikörper gegen den p2x7-rezeptor und fragmente davon
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (de) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Haustier krebst therapien mit einem anti p2x7 antikörper
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US10654926B2 (en) * 2014-05-02 2020-05-19 Medimmune Limited P2X4 antibodies and uses thereof
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (de) 1999-02-26 2005-01-19 Smithkline Beecham Corp KLONIERUNG EINES P2Y-äHNLICHEN 7TM-REZEPTORS (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) * 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Also Published As

Publication number Publication date
ZA200304853B (en) 2004-02-19
CA2431362A1 (en) 2002-06-20
DE60138415D1 (de) 2009-05-28
US20080227122A1 (en) 2008-09-18
AUPR201500A0 (en) 2001-01-11
JP4334223B2 (ja) 2009-09-30
EP1352085A4 (de) 2004-05-06
US20040067542A1 (en) 2004-04-08
CN100448486C (zh) 2009-01-07
EP1352085B1 (de) 2009-04-15
JP2009143933A (ja) 2009-07-02
JP2004520025A (ja) 2004-07-08
EP1352085A1 (de) 2003-10-15
CN1533440A (zh) 2004-09-29
WO2002048395A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
ATE428803T1 (de) Expression von p2y-purinergem rezeptor zur identifizierung präneoplastischer und neoplastischer zustände
CY1111042T1 (el) Μεθοδος απομονωσης βλαστικων κυτταρων
ATE321088T1 (de) Polysiloxanpolymere, verfahren zu ihrer herstellung und ihre verwendung
DE69939820D1 (de) Internalisierende erbb2 antikörper
ATE351921T1 (de) Verfahren für fluoreszenzerkennungstest
EP1131333A4 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69922038D1 (de) Herstellungsverfahren für retroreflektierende elemente mit erhöhter rückstreuung unter nassen bedingungen
DE69942520D1 (de) Verfahren zur herstellung von negativen elektroden für sekundärbatterien
ATE424560T1 (de) Marker für neuromyelitis optica
TR200401348T4 (tr) Yapay elyaf halatların kontrol edilmesi için elektrik kontağı
DE60134692D1 (de) Beleuchtungsanordnung für Tastaturen und die dynamische bzw. individuelle Beleuchtung der Tasten sowie Verfahren zu ihrer Verwendung
DE69806658D1 (de) Vorrichtung für die Reformierung von Kraftstoffen
ES2185740T3 (es) Dispositivo de fijacion superficial.
ATE456799T1 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
TR200101326T2 (tr) Fiber optik bağlantı kapağı ve ilgili metodlar
DK0901522T3 (da) Immortaliserede aviære celler
DE69923226D1 (de) Beschleunigungsaufnehmer für autoreifen
EP1450602A4 (de) Identifizierung und charakterisierung von genen
DE69829240D1 (de) Für temperaturstabiles Diaphorase Kodierendes Gen
PT1127133E (pt) Polipeptido que proporciona permeabilidade celular
DE69602187D1 (de) Natürliches Pauspapier für die Verwendung von Farbstoffen.
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
SE0201750D0 (sv) Selective Chromophores
NO20024575D0 (no) Fluorescerende kontaktlinser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties